FEATURE: As Pipelines Wither, Pharma and FDA Explore Whether Microarrays are Ready for Primetime | GenomeWeb

This is the first in a two-part series that examines how--or whether--drug companies and the US Food and Drug Administration can use microarray data in the drug-approval process. Today's installment covers whether microarray technology has a place in the later stages of drug development, while tomorrow's article will explore how the FDA and pharma firms plan to usher the technology into the mainstream.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.